<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1951">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135767</url>
  </required_header>
  <id_info>
    <org_study_id>2011002840</org_study_id>
    <secondary_id>P20GM130414</secondary_id>
    <nct_id>NCT05135767</nct_id>
  </id_info>
  <brief_title>Biobehavioral Pathways Underlying Alcohol Use and Health</brief_title>
  <official_title>Biobehavioral Pathways Underlying Alcohol Use and Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol-associated liver disease (AALD) and alcohol use disorder (AUD) are intersecting&#xD;
      diseases that add substantially to the global burden of disease and mortality. AALD refers to&#xD;
      a spectrum of liver tissue injury caused by chronic and excessive alcohol use. Although&#xD;
      reducing drinking is a main treatment goal, this is often unachievable for many AALD patients&#xD;
      due to an underlying AUD characterized by craving, negative affect, and alcohol seeking&#xD;
      despite harms. While numerous, high-quality studies demonstrate effectiveness of brief&#xD;
      psychosocial interventions for AUD, few trials have tested the efficacy of psychosocial&#xD;
      interventions to reduce drinking in AALD patients. This study unites a team of addiction&#xD;
      scientists and hepatologists to form a partnership for future work testing AUD interventions&#xD;
      integrated with AALD care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this project is to demonstrate the feasibility of implementing a brief&#xD;
      motivational intervention targeting alcohol use for patients with alcohol-associated liver&#xD;
      disease (AALD). The intervention will include personalized feedback from biomarkers of liver&#xD;
      function, drinking patterns, and self-monitoring via smartphone reports in daily life.&#xD;
      Participants (n=44) will exceed moderate drinking guidelines and will be recruited from local&#xD;
      hospitals and the community. This is a parallel group design in which all participants&#xD;
      receive the same intervention. Half of the participants will have AALD and meet criteria for&#xD;
      AUD, and half will have AUD only without evidence of advanced liver disease. The protocol&#xD;
      includes a 1-week screening phase, 3-week intervention phase, and 3-month follow-up. In&#xD;
      addition to demonstrating feasibility, this project aims to test whether behavioral&#xD;
      endophenotypes associated with alcohol-use outcomes in clinical trials are more resistant to&#xD;
      change during AUD intervention for AALD patients with AUD relative to those with AUD only. A&#xD;
      final aim is to explore biomarkers of inflammation and immune activation as mechanisms of&#xD;
      persistence of endophenotypes, specifically levels of pro-inflammatory cytokines, chemokines,&#xD;
      and others implicated in the pathogenesis of AALD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Enrolled Per Month</measure>
    <time_frame>24 months</time_frame>
    <description>Feasibility will be evaluated through the pace of recruitment, i.e., the number participants recruited per month. The target is two participants enrolling in the study per month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Screen Eligible Who Enroll</measure>
    <time_frame>24 months</time_frame>
    <description>Feasibility will be evaluated through the percentage of those who are screened as eligible for the study who enroll as participants in the study. The target enrollment rate is greater than or equal to 60% of screen eligible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Complete the Study</measure>
    <time_frame>24 months</time_frame>
    <description>Feasibility will be evaluated through the percentage of those participants who are enrolled in the study who complete the study. The target retention rate is greater than or equal to 70% of enrolled participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Withdraw</measure>
    <time_frame>24 months</time_frame>
    <description>Acceptability will be evaluated through the percentage of those participants who enroll in the study who withdraw from the study. A participant is considered to have withdrawn from the study if they indicate that they no longer wish to be a part of the study (i.e., not lost to contact). The target withdrawal rate is less than or equal to 20% of enrolled participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving in Daily Life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Ecological momentary assessment (EMA) is a method for collecting self-monitoring data using smartphones. Participants will complete smartphone reports for a total of 4 weeks including a 1-week screening phase and 3-week intervention phase.Participants will self-monitor and rate the intensity of their alcohol craving in daily life. They will also indicate situational and contextual factors, including the presence of visible alcohol cues. Craving will be assessed using a visual analogue scale from 0 to 10 via the question, &quot;How strong is your craving to drink alcohol right now?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving in the Human Laboratory</measure>
    <time_frame>20 minutes</time_frame>
    <description>Participants will be exposed to alcohol and water cues in the human laboratory via a standardized in vivo cue reactivity paradigm. The participant's typical alcoholic beverage is used as the in vivo alcohol cue. Each cue exposure lasts approximately 90 seconds. An initial relaxation period is followed by exposure to the water cue, and two repeated exposures to the alcohol cue. To match assessment of craving in daily life, craving will be assessed using a visual analogue scale from 0 to 10 via the question, &quot;How strong is your craving to drink alcohol right now?&quot;. Craving will also be assessed with the Alcohol Craving Questionnaire--Short Form-Revised (ACQ-SF-R), a 12-item self-administered, multidimensional state measure of acute alcohol craving.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Alcohol Use Disorder Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in the Alcohol Use Disorder Only arm will meet criteria for alcohol use disorder but will not show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol Associated Liver Disease + Alcohol Use Disorder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in the Alcohol Associated Liver Disease + Alcohol Use Disorder arm will meet criteria for alcohol use disorder and also show evidence of advanced alcohol-associated liver disease. Both arms receive the same brief motivational intervention with personalized feedback.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Motivational Interviewing with Personalized Feedback</intervention_name>
    <description>A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60 minute session, two brief, 5-10 minute check-ins, and a 30 minute booster session.</description>
    <arm_group_label>Alcohol Associated Liver Disease + Alcohol Use Disorder</arm_group_label>
    <arm_group_label>Alcohol Use Disorder Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria. To be eligible, the interested volunteer must:&#xD;
&#xD;
          1. Be at least 18 years of age.&#xD;
&#xD;
          2. Meet the Diagnostic and Statistical Manual-5 criteria for alcohol use disorder,&#xD;
             indicated by meeting 2 or more symptom criteria.&#xD;
&#xD;
          3. If male, report an average of 14 or more standard alcoholic drinks per week, or if&#xD;
             female, report an average of 7 or more standard alcoholic drinks per week.&#xD;
&#xD;
          4. Be able to speak and read English or Spanish in order to provide written informed&#xD;
             consent and understand written and oral instructions in English or Spanish.&#xD;
&#xD;
        General Exclusion Criteria. Interested volunteers must not have any of the following:&#xD;
&#xD;
          1. Meet the Diagnostic and Statistical Manual-5 criteria for a current or lifetime&#xD;
             diagnosis of psychotic disorders.&#xD;
&#xD;
          2. Meet the Diagnostic and Statistical Manual-5 criteria for a current major depressive&#xD;
             episode or bipolar disorder.&#xD;
&#xD;
          3. Currently receiving specialized psychosocial treatment for an alcohol-use or drug&#xD;
             problem.&#xD;
&#xD;
          4. If female, pregnant or nursing.&#xD;
&#xD;
          5. Be anyone who, in the opinion of the investigative team, could not currently be safely&#xD;
             withdrawn from alcohol without medical detoxification.&#xD;
&#xD;
          6. A BMI of 40 or more, or 35 or more and experiencing obesity-related health conditions,&#xD;
             such as high blood pressure or diabetes.&#xD;
&#xD;
          7. Known medical conditions that, in the opinion of the investigative team, would&#xD;
             confound results (e.g., uncontrolled infections, multiorgan failure, uncontrolled&#xD;
             upper gastrointestinal bleeding, hepatocellular carcinoma or other active malignancies&#xD;
             except skin cancer).&#xD;
&#xD;
          8. Patients who have received a liver transplant or are too ill to participate.&#xD;
&#xD;
          9. Pre-existing loss of kidney function with estimated glomerular filtration rate &lt; 30.&#xD;
&#xD;
         10. Any other condition that, in the opinion of the investigative team, would make the&#xD;
             interested volunteer unsuitable for the study or unable to comply with the&#xD;
             requirements.&#xD;
&#xD;
        Additional Inclusion Criteria for the AALD + AUD Arm.&#xD;
&#xD;
        To be eligible in the AALD+AUD group, the interested volunteer must be diagnosed with&#xD;
        advanced alcohol-associated liver disease. AALD will be determined by chart review.&#xD;
        Interested volunteers must have one of the following:&#xD;
&#xD;
          1. Positive liver biopsy, or&#xD;
&#xD;
          2. FibroscanÂ® score &gt; 12.5, or&#xD;
&#xD;
          3. Evidence of a nodular liver or portal hypertension on abdominal imaging, or&#xD;
&#xD;
          4. Presence of portal hypertensive complications such as hepatic encephalopathy, ascites,&#xD;
             or varices, or&#xD;
&#xD;
          5. Fibrosis-4 index &gt;= 3.25, or&#xD;
&#xD;
          6. Aspartate transaminase-platelet ratio index &gt;= 1.0.&#xD;
&#xD;
        Additional Exclusion Criteria for the AUD Only Arm. To be eligible in the AUD-only group,&#xD;
        the interested volunteer must not show the following diagnostic test results indicating&#xD;
        advanced, alcoholic fibrosis &gt;=F3.&#xD;
&#xD;
          1. Fibrosis-4 index &gt;= 3.25*, or&#xD;
&#xD;
          2. Aspartate transaminase-platelet ratio index &gt;= 1.0**, or&#xD;
&#xD;
          3. Gamma-glutamyl transpeptidase-to-platelet ratio &gt;= 0.32.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hayley Treloar Padovano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hayley Treloar Padovano, PhD</last_name>
    <phone>4018636623</phone>
    <email>hayley_treloar@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brown University School of Public Health</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hayley Treloar Padovano, PhD</last_name>
      <phone>401-863-6623</phone>
      <email>hayley_treloar@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Hayley Treloar Padovano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kittichai Promrat, MD</last_name>
      <phone>401-273-7100</phone>
      <phone_ext>3456</phone_ext>
      <email>kittichai_promrat@brown.edu</email>
    </contact>
    <investigator>
      <last_name>Kittichai Promrat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol Use Disorder</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Craving</keyword>
  <keyword>Ecological Momentary Assessment</keyword>
  <keyword>Biobehavioral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be kept and used for future research on chronic disease and substance use. This includes biospecimens.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Core data including biospecimens collected to fulfill the aims of the Center for Addiction and Disease Risk Exacerbation will be available to request immediately following publication with no prespecified end date. Project-specific data collected to fulfill the research aims outlined in this clinical trial registration will be made available beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>After all data are collected and the results of the study are published, deidentified data and biospecimens may be made available to other qualified investigators at Brown or other institutions upon request. The request will be evaluated by the investigators to ensure that it meets reasonable demands of scientific integrity.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

